A hallmark feature of tumorigenesis is the global shift in metabolism. The ability to easily measure metabolism in situ could provide a powerful strategy for the early detection of cancers, as well as the ability to better diagnose and prognosticate cancers based on the detection of certain metabolic signatures related to specific oncogene expression and finally could uncover novel molecular underpinnings of cancer that could serve as better therapeutic targets. The MYC oncogene is one of the most commonly implicated causes of human tumorigenesis, in particular associated with the pathogenesis of hematopoietic tumors including lymphoma and epithelial tumors such as hepatocellular carcinoma. MYC contributes to tumorigenesis by functioning as a global regulator of transcription involving many cellular programs, in particular, cellular proliferation, growth and metabolism associated with the Warburg effect. MYC regulates key genes in glycolysis, glutaminolysis, tricarboxylic acid cycle, C1/folate, purine, pyrimidine and, notably, lipid metabolism. This suggests that in situ analysis of specific metabolic signatures could be a highly useful approach to detect, diagnose and prognosticate MYC-associated human tumors. However, using existing methods, it has not been readily possible to perform an in situ analysis of metabolism. Now, we have developed a highly sensitive approach that will enable us to use an innovative form of mass spectrometry to provide microscopic examination of the MYC-induced cancer metabolism. A key feature of this analysis is the ability to provide essentially rea time, in situ analysis. The method - called Desorption Electrospray Ionization Mass Spectrometry Imaging (DESI-MSI) - bombards cells and/or tissue sections with microdroplets containing acetonitrile and dimethylformamide that dissolve hundreds of lipids and metabolites. In this proposal, we will use DESI-MSI as a tool for identifying metabolic signatures causally associated with MYC expression in lymphomas. We will use this approach to decipher the biological mechanism by which MYC generates cancers thought the identified metabolites.

Public Health Relevance

The ability to easily measure metabolism in situ could provide a powerful strategy for the early detection of cancers, as well as the ability to better diagnose and prognosticate cancers based on the detection of certain metabolic signatures related to specific oncogene expression and could uncover novel molecular underpinnings of cancer that could serve as better therapeutic targets. Now, we have developed a highly sensitive approach that will enable us to use an innovative form of mass spectrometry called Desorption Electrospray Ionization Mass Spectrometry Imaging (DESI-MSI). We will use this approach to decipher the biological mechanism by which MYC generates cancers thought the identified metabolites.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA184384-01
Application #
8673796
Study Section
Enabling Bioanalytical and Imaging Technologies Study Section (EBIT)
Program Officer
Jessup, John M
Project Start
2014-04-04
Project End
2019-02-28
Budget Start
2014-04-04
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$569,601
Indirect Cost
$203,879
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Neumann, S Ephraim; Chamberlayne, Christian F; Zare, Richard N (2018) Electrically controlled drug release using pH-sensitive polymer films. Nanoscale 10:10087-10093
Dhanasekaran, Renumathy; Gabay-Ryan, Meital; Baylot, Virginie et al. (2018) Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget 9:5517-5528
Hebb, Jonathan P O; Mosley, Adriane R; Vences-Catalán, Felipe et al. (2018) Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother 67:47-60
Gouw, Arvin M; Eberlin, Livia S; Margulis, Katherine et al. (2017) Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A 114:4300-4305
Gouw, Arvin M; Toal, Georgia G; Felsher, Dean W (2016) Metabolic vulnerabilities of MYC-induced cancer. Oncotarget 7:29879-80
Eberlin, Livia S; Margulis, Katherine; Planell-Mendez, Ivette et al. (2016) Pancreatic Cancer Surgical Resection Margins: Molecular Assessment by Mass Spectrometry Imaging. PLoS Med 13:e1002108
Casey, Stephanie C; Tong, Ling; Li, Yulin et al. (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227-31
Shroff, Emelyn H; Eberlin, Livia S; Dang, Vanessa M et al. (2015) MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A 112:6539-44
Goodson 3rd, William H; Lowe, Leroy; Carpenter, David O et al. (2015) Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis 36 Suppl 1:S254-96
Hsu, Cheng-Chih; Chou, Pi-Tai; Zare, Richard N (2015) Imaging of Proteins in Tissue Samples Using Nanospray Desorption Electrospray Ionization Mass Spectrometry. Anal Chem 87:11171-5

Showing the most recent 10 out of 12 publications